Skip to main content
Premium Trial:

Request an Annual Quote

Belgian Researchers Collaborate on Development of MDx for Sudden Cardiac Death

NEW YORK (GenomeWeb) – Researchers affiliated with the University of Antwerp and Antwerp University Hospital have partnered with molecular diagnostics firm Multiplicom to develop a test to help identify individuals at risk for sudden cardiac death.

The test called PED MASTR is already being used at the center of medical genetics at the university and university hospital and will be fully launched in September.

SCD affects about one in every 1,000 people, with heart rhythm abnormalities associated with the condition difficult to detect. The PED MASTR test allows for the rapid analysis of genes involved in SCD-causing mutations, the partners said, adding that family members of affected individuals have a 50-50 chance of inheriting the same genetic predisposition for developing cardiac disease.

PED MASTR comprises 51 genes, allowing physicians to identify all genetic mutations for SCD simultaneously, and then to prescribe appropriate treatments, Multiplicom CEO Dirk Pollet said in a statement.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.